ProfileGDS4814 / ILMN_1875606
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 6% 24% 32% 23% 23% 14% 22% 13% 21% 28% 12% 18% 18% 31% 20% 14% 10% 18% 28% 30% 11% 20% 9% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)39.66516
GSM780708Untreated after 4 days (C2_1)44.432724
GSM780709Untreated after 4 days (C3_1)45.930132
GSM780719Untreated after 4 days (C1_2)44.143823
GSM780720Untreated after 4 days (C2_2)44.189223
GSM780721Untreated after 4 days (C3_2)42.243314
GSM780710Trastuzumab treated after 4 days (T1_1)43.86922
GSM780711Trastuzumab treated after 4 days (T2_1)42.091313
GSM780712Trastuzumab treated after 4 days (T3_1)43.863821
GSM780722Trastuzumab treated after 4 days (T1_2)45.18528
GSM780723Trastuzumab treated after 4 days (T2_2)41.669412
GSM780724Trastuzumab treated after 4 days (T3_2)43.198818
GSM780713Pertuzumab treated after 4 days (P1_1)43.025218
GSM780714Pertuzumab treated after 4 days (P2_1)45.825431
GSM780715Pertuzumab treated after 4 days (P3_1)43.654720
GSM780725Pertuzumab treated after 4 days (P1_2)42.212514
GSM780726Pertuzumab treated after 4 days (P2_2)41.046810
GSM780727Pertuzumab treated after 4 days (P3_2)43.139318
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)45.208628
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)45.508830
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)41.535911
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)43.456820
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)40.78979